|1||NCT01869114||Recruiting||Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy||
||83||All||18 Years and older (Adult, Senior)||NCT01869114||12D.587
|July 8, 2013||July 8, 2018||January 2020||June 5, 2013||December 6, 2017||
|2||NCT01291745||Unknown †||Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES||
||200||All||18 Years and older (Adult, Senior)||NCT01291745||O-MDS-PROTOCOL||O-MDS-Protocol||September 2010||September 2013||September 2015||February 8, 2011||February 8, 2011||
† Study has passed its completion date and status has not been verified in more than two years.